Works by Lublin, Fred


Results: 96
    1
    2
    3

    Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.

    Published in:
    JAMA Neurology, 2021, v. 78, n. 5, p. 558, doi. 10.1001/jamaneurol.2021.0405
    By:
    • Kappos, Ludwig;
    • Fox, Robert J.;
    • Burcklen, Michel;
    • Freedman, Mark S.;
    • Havrdová, Eva K.;
    • Hennessy, Brian;
    • Hohlfeld, Reinhard;
    • Lublin, Fred;
    • Montalban, Xavier;
    • Pozzilli, Carlo;
    • Scherz, Tatiana;
    • D'Ambrosio, Daniele;
    • Linscheid, Philippe;
    • Vaclavkova, Andrea;
    • Pirozek-Lawniczek, Magdalena;
    • Kracker, Hilke;
    • Sprenger, Till
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12

    The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

    Published in:
    Journal of Neurology, 2009, v. 256, n. 3, p. 405, doi. 10.1007/s00415-009-0093-1
    By:
    • Hutchinson, Michael;
    • Kappos, Ludwig;
    • Calabresi, Peter A.;
    • Confavreux, Christian;
    • Giovannoni, Gavin;
    • Galetta, Steven L.;
    • Havrdova, Eva;
    • Lublin, Fred D.;
    • Miller, David H.;
    • O'Connor, Paul W.;
    • Phillips, J. Theodore;
    • Polman, Chris H.;
    • Radue, Ernst-Wilhelm;
    • Rudick, Richard A.;
    • Stuart, William H.;
    • Wajgt, Andrzej;
    • Weinstock-Guttman, Bianca;
    • Wynn, Daniel R.;
    • Lynn, Frances;
    • Panzara, Michael A.
    Publication type:
    Article
    13
    14

    Genetic Regulation of Susceptibility and Severity of Demyelinationa.

    Published in:
    Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 735, doi. 10.1111/j.1749-6632.1988.tb27230.x
    By:
    • KNOBLER, ROBERT L.;
    • LUBLIN, FRED D.;
    • LINTHICUM, D. SCOTT;
    • COHN, MEL;
    • MELVOLD, ROGER D.;
    • LIPTON, HOWARD L.;
    • TAYLOR, BENJAMIN A.;
    • BEAMER, WESLEY G.
    Publication type:
    Article
    15
    16
    17

    Neuroendocrine Regulation of Immune Parameters.

    Published in:
    Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 704, doi. 10.1111/j.1749-6632.1988.tb27219.x
    By:
    • BRAINARD, GEORGE C.;
    • WATSON-WHITMEYER, MARCIA;
    • KNOBLER, ROBERT L.;
    • LUBLIN, FRED D.
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24

    Cerebellar volume as imaging outcome in progressive multiple sclerosis.

    Published in:
    PLoS ONE, 2017, v. 12, n. 4, p. 1, doi. 10.1371/journal.pone.0176519
    By:
    • Inglese, Matilde;
    • Petracca, Maria;
    • Mormina, Enricomaria;
    • Achiron, Anat;
    • Straus-Farber, Rebecca;
    • Miron, Shmuel;
    • Fabian, Michelle;
    • Krieger, Stephen;
    • Miller, Aaron;
    • Lublin, Fred;
    • Sormani, Maria Pia
    Publication type:
    Article
    25

    Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

    Published in:
    Brain: A Journal of Neurology, 1999, v. 122, n. 5, p. 871, doi. 10.1093/brain/122.5.871
    By:
    • Cutter, Gary R.;
    • Baier, Monika L.;
    • Rudick, Richard A.;
    • Cookfair, Diane L.;
    • Fischer, Jill S.;
    • Petkau, John;
    • Syndulko, Karl;
    • Weinshenker, Brian G.;
    • Antel, Jack P.;
    • Confavreux, Christian;
    • Ellison, George W.;
    • Lublin, Fred;
    • Miller, Aaron E.;
    • Rao, Stephen M.;
    • Reingold, Stephen;
    • Thompson, Alan;
    • Willoughby, Ernest
    Publication type:
    Article
    26
    27

    Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

    Published in:
    2001
    By:
    • McDonald, W. Ian;
    • Compston, Alistair;
    • Edan, Gilles;
    • Goodkin, Donald;
    • Hartung, Hans-Peter;
    • Lublin, Fred D.;
    • McFarland, Henry F.;
    • Paty, Donald W.;
    • Polman, Chris H.;
    • Reingold, Stephen C.;
    • Sandberg-Wollheim, Magnhild;
    • Sibley, William;
    • Thompson, Alan;
    • Van Den Noort, Stanley;
    • Weinshenker, Brian Y.;
    • Wolinsky, Jerry S.;
    • McDonald, W I;
    • Compston, A;
    • Edan, G;
    • Goodkin, D
    Publication type:
    journal article
    28
    29
    30
    31

    Clinical outcomes assessment in multiple sclerosis.

    Published in:
    Annals of Neurology, 1996, v. 40, n. 3, p. 469, doi. 10.1002/ana.410400321
    By:
    • Rudick, Richard;
    • Fischer, Jill;
    • Antel, Jack;
    • Confavreux, Christian;
    • Cutter, Gary;
    • Ellison, George;
    • Lublin, Fred;
    • Miller, Aaron;
    • Petkau, John;
    • Rao, Stephen;
    • Reingold, Stephen;
    • Syndulko, Karl;
    • Thompson, Alan;
    • Wallenberg, Joy;
    • Weinshenker, Brain;
    • Willoughby, Ernest
    Publication type:
    Article
    32
    33

    Autoimmune inflammation of astrocyte transplants.

    Published in:
    Annals of Neurology, 1992, v. 31, n. 5, p. 519, doi. 10.1002/ana.410310510
    By:
    • Lublin, Fred D.;
    • Marini, Joseph C.;
    • Perreault, Marielle;
    • Olender, Christina;
    • D'Imperio, Concetta;
    • Joseph, Jeymohan;
    • Korngold, Robert;
    • Knobler, Robert L.
    Publication type:
    Article
    34
    35
    36
    37

    (DXT15) Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the N-MOmentum Trial.

    Published in:
    International Journal of MS Care, 2020, v. 22, n. S2, p. 21
    By:
    • Wingerchuk, Dean;
    • Marignier, Romain;
    • Bennett, Jeffrey L.;
    • Ho Jin Kim;
    • Weinshenker, Brian;
    • Pittock, Sean J.;
    • Kazuo Fujihara;
    • Paul, Friedemann;
    • Cutter, Gary;
    • Green, Ari;
    • Aktas, Orhan;
    • Hartung, Hans-Peter;
    • Lublin, Fred D.;
    • Mealy, Maureen A.;
    • Drappa, Jorn;
    • Barron, Gerard;
    • Madani, Soraya;
    • Dewei She;
    • Cimbora, Daniel;
    • Rees, William
    Publication type:
    Article
    38
    39

    A Framework of Care in Multiple Sclerosis, Part 2.

    Published in:
    International Journal of MS Care, 2017, v. 19, n. 1, p. 42, doi. 10.7224/1537-2073.2016-062
    By:
    • Newsome, Scott D.;
    • Aliotta, Philip J.;
    • Bainbridge, Jacquelyn;
    • Bennett, Susan E.;
    • Cutter, Gary;
    • Fenton, Kaylan;
    • Lublin, Fred;
    • Northrop, Dorothy;
    • Rintell, David;
    • Walker, Bryan D.;
    • Weigel, Megan;
    • Zackowski, Kathleen;
    • Jones, David E.
    Publication type:
    Article
    40

    A Framework of Care in Multiple Sclerosis, Part 1.

    Published in:
    International Journal of MS Care, 2016, v. 18, n. 6, p. 314, doi. 10.7224/1537-2073.2016-051
    By:
    • Newsome, Scott D.;
    • Aliotta, Philip J.;
    • Bainbridge, Jacquelyn;
    • Bennett, Susan E.;
    • Cutter, Gary;
    • Fenton, Kaylan;
    • Lublin, Fred;
    • Northrop, Dorothy;
    • Rintell, David;
    • Walker, Bryan D.;
    • Weigel, Megan;
    • Zackowski, Kathleen;
    • Jones, David E.
    Publication type:
    Article
    41

    Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

    Published in:
    2012
    By:
    • Cook, Stuart D.;
    • Dhib-Jalbut, Suhayl;
    • Dowling, Peter;
    • Durelli, Luca;
    • Ford, Corey;
    • Giovannoni, Gavin;
    • Halper, June;
    • Harris, Colleen;
    • Herbert, Joseph;
    • Li, David;
    • Lincoln, John A.;
    • Lisak, Robert;
    • Lublin, Fred D.;
    • Lucchinetti, Claudia F.;
    • Moore, Wayne;
    • Naismith, Robert T.;
    • Oehninger, Carlos;
    • Simon, Jack;
    • Sormani, Maria Pia
    Publication type:
    Journal Article
    42
    43

    No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-la.

    Published in:
    Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 2, p. 1, doi. 10.1177/2055217318760642
    By:
    • Havrdová, Eva;
    • Arnold, Douglas L.;
    • Bar-Or, Amit;
    • Comi, Giancarlo;
    • Hartung, Hans-Peter;
    • Kappos, Ludwig;
    • Lublin, Fred;
    • Selmaj, Krzysztof;
    • Traboulsee, Anthony;
    • Belachew, Shibeshih;
    • Bennett, Iain;
    • Buffels, Regine;
    • Garren, Hideki;
    • Han, Jian;
    • Julian, Laura;
    • Napieralski, Julie;
    • Hauser, Stephen L.;
    • Giovannoni, Gavin
    Publication type:
    Article
    44

    No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

    Published in:
    Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 1, p. 1, doi. 10.1177/2055217318760642
    By:
    • Havrdová, Eva;
    • Arnold, Douglas L.;
    • Bar-Or, Amit;
    • Comi, Giancarlo;
    • Hartung, Hans-Peter;
    • Kappos, Ludwig;
    • Lublin, Fred;
    • Selmaj, Krzysztof;
    • Traboulsee, Anthony;
    • Belachew, Shibeshih;
    • Bennett, Iain;
    • Buffels, Regine;
    • Garren, Hideki;
    • Han, Jian;
    • Julian, Laura;
    • Napieralski, Julie;
    • Hauser, Stephen L.;
    • Giovannoni, Gavin
    Publication type:
    Article
    45
    46
    47
    48
    49
    50